denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Description:
As our understanding of the molecular underpinnings of aggressive lymphomas has grown, the identification of novel therapies targeting biological drivers of disease have also been recognized. It remains to be understood however, how these novel therapies will fit into practice. Should our efforts be focused on specific drivers for individual cell of origin subtypes, reversing chemoresistance, or harnessing antitumor immunity? Despite the fast pace nature of the scientific advances in this field, we are still waiting for breakthrough treatment strategies for aggressive lymphoma.
This education session will explore the emerging evidence of epigenetic drivers of disease and how epigenetics relates to lymphomas that become refractory to chemotherapy. In addition, this session will dissect how epigenetic therapies can be utilized to overcome chemoresistance and enhance immunotherapy. Finally, cutting-edge novel therapeutics and strategies for targeting aggressive lymphomas will be discussed in detail.
Dr. Michael Green will discuss recent advances in our understanding of the role of epigenetics in the development of lymphoma. Focusing on follicular and diffuse large B-cell lymphomas, he will discuss the cellular and molecular mechanisms by which somatic mutations alter the lymphoma epigenome and drive lymphomagenesis. The discussion will be centered on how this knowledge can be leveraged to design rational therapeutic strategies for patients with lymphoma.
Dr. Jennifer Amengual will discuss principles of chemotherapy resistance and insights into how epigenetics has been implicated in the emergence of resistant clones. She will discuss how epigenetics relates to immune evasion in aggressive lymphomas. Finally, Dr. Amengual will review how epigenetic modulation can resensitize lymphoma to chemotherapy and novel agents as well as enhance antitumor immunity to potentiate immunotherapy.
Dr. Kami Maddocks will discuss novel approaches in the treatment of aggressive lymphomas. She will discuss potential targets for therapy in aggressive non-Hodgkin lymphoma including various immunological, signaling and mutation targets. Focusing on aggressive B-cell lymphomas, she will review emerging therapies in development for the treatment of relapsed/refractory NHL including results from the most promising clinical trials.
This education session will explore the emerging evidence of epigenetic drivers of disease and how epigenetics relates to lymphomas that become refractory to chemotherapy. In addition, this session will dissect how epigenetic therapies can be utilized to overcome chemoresistance and enhance immunotherapy. Finally, cutting-edge novel therapeutics and strategies for targeting aggressive lymphomas will be discussed in detail.
Dr. Michael Green will discuss recent advances in our understanding of the role of epigenetics in the development of lymphoma. Focusing on follicular and diffuse large B-cell lymphomas, he will discuss the cellular and molecular mechanisms by which somatic mutations alter the lymphoma epigenome and drive lymphomagenesis. The discussion will be centered on how this knowledge can be leveraged to design rational therapeutic strategies for patients with lymphoma.
Dr. Jennifer Amengual will discuss principles of chemotherapy resistance and insights into how epigenetics has been implicated in the emergence of resistant clones. She will discuss how epigenetics relates to immune evasion in aggressive lymphomas. Finally, Dr. Amengual will review how epigenetic modulation can resensitize lymphoma to chemotherapy and novel agents as well as enhance antitumor immunity to potentiate immunotherapy.
Dr. Kami Maddocks will discuss novel approaches in the treatment of aggressive lymphomas. She will discuss potential targets for therapy in aggressive non-Hodgkin lymphoma including various immunological, signaling and mutation targets. Focusing on aggressive B-cell lymphomas, she will review emerging therapies in development for the treatment of relapsed/refractory NHL including results from the most promising clinical trials.